What it is
Regulatory status: FDA-approved prescription biologic for LDL-C reduction and cardiovascular-risk reduction in labelled populations
Mechanism evidence: human
At a glance
What it is, why people use it, the evidence, and what to know before trying it.
Why people use it
- LDL cholesterol reduction
- Reduction of major cardiovascular events in higher-risk adults
Evidence at a glance
Evolocumab has strong evidence and regulatory approval for substantial LDL-C lowering and cardiovascular-event reduction in indicated patients. That does not make it a general longevity drug for low-risk people.
Confidence: strong
Clinical safety
Contraindications, interactions and clinical cautions from reviewed sources.
Common reactions include injection-site and upper-respiratory symptoms; serious hypersensitivity can occur. Treatment requires diagnosis, lipid monitoring, correct storage and injection technique, and clinician oversight.
Forms and variants
This review does not automatically apply to:
- alirocumab
- inclisiran
- oral lipid-lowering medicines
Seen in protocols
Public protocols that include Evolocumab. Open one to see the full context and source.